R&D Committee. Pharmos and BLP agree to expand the scope of the ------------- Research and Development Committee formed pursuant to the U.S. Marketing Agreement with respect to the performance of the R&D Plans for the New Territories. The Committee membership will remain as currently constituted. The Committee will monitor and evaluate the performance of the R&D Plans by both parties. The Committee shall remain the primary forum for the resolution of disputes between the parties with respect to research and development matters which are not otherwise addressed in this Agreement or any other agreements between the parties, provided that the failure of the Committee to resolve any -------- such dispute shall not constitute a default under, or breach of, this Agreement.

R&D Committee. Promptly after the Effective Date, each PARTY shall appoint a representative to serve as a member of a research and development committee (the “R&D COMMITTEE”). The R&D COMMITTEE shall meet quarterly and, on an exceptional basis, from time to time promptly after the date of a written request by either PARTY. SYNERON’s initial member of the R&D COMMITTEE shall be Xxxxxxx Xxxxxxxx. P&G’s initial member shall be Xxxx Xxxxxx. Either PARTY may change its R&D COMMITTEE member upon written notice to the other PARTY. The R&D COMMITTEE may meet in person or by teleconference or videoconference. It shall be chaired on an alternating basis by the SYNERON member or P&G member. The chair of the R&D COMMITTEE at the time of each meeting shall prepare draft minutes of such meeting for circulation to other member of the R&D COMMITTEE within two (2) weeks after such meeting, and shall issue final minutes incorporating suggested changes and/or noting disagreements as requested by the other member of the R&D COMMITTEE within two (2) weeks after such draft minutes were circulated.

R&D Committee. The Parties will establish and maintain a joint research and development committee (the “R&D Committee”) to oversee the conduct of the Collaboration, including, but not limited to approving any changes to the R&D Plan and R&D Budget. The R&D Committee will be established, operated and governed in accordance with the policies and procedures set forth in APPENDIX 5 attached hereto [***] may be amended with the unanimous approval of the R&D Committee members. As needed, the R&D Committee will establish subcommittees and working groups that will report to the R&D Committee to further the objectives of the Collaboration. The R&D Committee and any subcommittees and working groups established by the R&D Committee will dissolve at the end of the Collaboration Term.

R&D Committee. 6.1 Within five (5) Business Days after the Effective Date, the parties shall establish a research and development committee (‘R&D Committee’). Each party may appoint up to four representatives to the R&D Committee as it considers appropriate. Each party shall promptly notify the other party of the representatives it has appointed to the R&D Committee, and each party may replace such representatives at any time upon reasonable prior written notice to the other party.

R&D Committee. The Board shall designate a research and development committee (the "R&D Committee"), which shall be composed of two or more members, at least one of whom shall be a Huawei Holding Director and at least one of whom shall be a 3Com Director, subject to the terms of Section 3.09. Regular meetings of the R&D Committee shall be held at least quarterly during each fiscal year. The purpose of the R&D Committee shall be to administer and otherwise make decisions with respect to research and development activities relating to and on behalf of the JVCO, including, to (a) discuss the research and development direction of the JVCO, the Huawei Parties and the 3Com Parties and determine product areas that are most suitable for the focus of the research and development efforts of the JVCO, (b) identify research and development projects that can be jointly undertaken by, and leverage the respective strengths of, the JVCO, the Huawei Parties and the 3Com Parties, (c) determine the research and development roadmap and resource allocation for the JVCO, (d) selectively consider outsourcing projects when neither the JVCO nor 3Com has the research and development capabilities to meet a particular market requirement, (e) ensure that research and development decisions are made quickly, with due consideration for time-to-market objectives, and (f) review disclosures regarding Inventions of the JVCO and make timely determinations regarding the filing, prosecution and maintenance of Intellectual Property Rights.

Related to R&D Committee

Steering Committee Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza. The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities:
Research Committee 2.2.1 Establishment and Functions of the RC. -------------------------------------
Transition Committee Prior to the Effective Time, the Parties shall establish a transition committee (the “Transition Committee”) that shall consist of an equal number of members designated by Baxter and Baxalta at all times, with each Party having the right to replace the Transition Committee members delegated by it from time to time and taking such efforts as are necessary from time to time to cause the Transition Committee to consist of an equal number of representatives of Baxter and Baxalta (in a total number determined from time to time by the Parties). The Transition Committee shall be responsible for monitoring and managing all matters related to any of the transactions contemplated by this Agreement or any Ancillary Agreements. The Transition Committee shall have the authority to (a) establish one or more subcommittees from time to time as it deems appropriate or as may be described in any Ancillary Agreements, with each such subcommittee comprised of an equal number of members representing each Party, and each such subcommittee having such scope of responsibility as may be determined by the Transition Committee from time to time; (b) delegate to any such committee any of the powers of the Transition Committee; and (c) to combine, modify the scope of responsibility of, and disband any such subcommittees, and to modify or reverse any such delegations. The Transition Committee shall establish general procedures for managing the responsibilities delegated to it under this Section 2.14, and may modify such procedures from time to time. All decisions by the Transition Committee or any subcommittee thereof shall be effective only with majority approval, and any such approval must include the approval of at least one member of the Transition Committee designated by Baxter and at least one member of the Transition Committee designated by Baxalta. The Parties shall utilize the procedures set forth in Article VII to resolve any matters as to which the Transition Committee is not able to reach a decision.
Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).
Joint Steering Committee [***] following the Effective Date [***], a joint steering committee (the “JSC”) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement.
Board Committees The Director hereby agrees to sit in the relevant committees of the Board and to perform all of the duties, services and responsibilities necessary thereunder.
Operating Committee 7.01 To coordinate the operation of their respective generating, transmission and substation facilities, in order that the advantages to be derived hereunder may be realized by the parties hereto to the fullest practicable extent, the parties shall establish a committee of authorized representatives to be known as the Operating Committee. Each of the parties shall designate in writing delivered to the other party, the person who is to act as its representative on said committee (and the person or persons who may serve as alternates whenever such representative is unable to act). Each of such representatives and alternates shall be persons familiar with the generating, transmission, and substation facilities of the system of the party he represents, and each shall be fully authorized (1) to cooperate with the other representative (or alternates) and (2) to determine and agree from time to time, in accordance with this agreement and with any other relevant agreements then in effect between the parties, upon the following:
Nominating Committee Subject to the provisions of Article X, the Nominating Committee shall consist of such number of Directors (none of whom shall be an employee of the Corporation) as may be determined from time to time by the Board. Subject to the provisions of Article X, the Committee shall review the qualifications of potential candidates for the Equity Directors and shall propose nominees for the Equity Directors who are nominated by the Board. Subject to the provisions of Article X, in making their nominations, the Nominating Committee and the Board of Directors shall take into consideration that (i) the Board of Directors shall have meaningful representation of a diversity of interests, including floor brokers, floor traders, futures commission merchants, producers, consumers, processors, distributors and merchandisers of commodities traded on Chicago Mercantile Exchange Inc. (the “Exchange”) or Board of Trade of the City of Chicago, Inc. (the “CBOT”), participants in a variety of pits or principal groups of commodities traded on the Exchange or the CBOT and other market users or participants; (ii) at least 10% of the members of Board of Directors shall be composed of persons representing farmers, producers, merchants or exporters of principal commodities traded on the Exchange or the CBOT; and (iii) at least 20% of the members of the Board of Directors shall be composed of persons who do not possess trading privileges on either the Exchange or the CBOT, are not salaried employees of the Corporation and are not officers, principals or employees who are involved in operating the futures exchange related business of a firm entitled to members’ rates on either the Exchange or the CBOT. Notwithstanding the foregoing, the Nominating Committee shall include the Chief Executive Officer of the Corporation as a nominee for an Equity Director at any annual meeting of shareholders at which his or her term is scheduled to expire; provided, that if such term expiration occurs during the Transition Period, the Chief Executive Officer shall be nominated as a CME Director. Subject to the provisions of Article X, a majority of the Nominating Committee shall constitute a quorum necessary to transact business.
Advisory Committee (a) The Partnership shall have a committee (the “Advisory Committee”) consisting of Fund Investors or their representatives or designees selected by the Managing General Partner; provided that no member of the Advisory Committee shall be an Affiliate of the Managing General Partner (or a designee or representative thereof). The Managing General Partner will meet with the Advisory Committee at least semi-annually to consult on various matters concerning the Partnership, including financial statements and appraisals, the status of existing investments and such other matters as the Managing General Partner may determine or any member of the Advisory Committee may reasonably propose.
Executive Committee (A) The Executive Committee shall be composed of not more than nine members who shall be selected by the Board of Directors from its own members and who shall hold office during the pleasure of the Board.

R&D Committee Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Related to R&D Committee